Stock of the Day

MeiraGTx (MGTX)

$7.30

+$0.47 (+6.9%)

Market Cap: $533.79M

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.

Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Recent News

• MeiraGTx Shares Hit 52-Week High After Blindness-Treatment Data Release (marketwatch.com)
• MeiraGTx announces publication of data on rAAV8.hRKp.AIPL1 efficacy (markets.businessinsider.com)
• MeiraGTx rises after publication of positive data from gene therapy trial for eye disorder (msn.com)
• MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy (globenewswire.com)